It’s very cool that our portfolio company ShotSpotter was just profiled in the Washington Post (ShotSpotter detection system documents 39,000 shooting incidents in the District). In Washington DC, ShotSpotter has 300 acoustic sensors across 20 square miles of the city, covering mainly the Southeast and Northeast of the District. ShotSpotter is a unique gunfire surveillance […]Read More
Our portfolio company Assurex Health, announced recently the publication of a groundbreaking analysis of pharmacogenomic data in the International Review of Psychiatry. The publication strongly validates the premise that the clinical use of genomic testing to help predict patient response to psychiatric medications significantly improves treatment outcomes. This is a key milestone in the continuing […]Read More
Our portfolio company Genalyte just announced the award of a government grant from the National Cancer Institute for the development of a diagnostic system using Genalyte’s proprietary biomarker technology (see Genalyte Expands into Cancer Profiling with $1 Million NCI Grant to Develop Cancer Biomarker Panel). This project is a significant validation of the company’s capability […]Read More
Big Data Guru and Stanford Medical School Professor Atul Butte, co-founder of Numedii had his work recently profiled in the journal SCIENCE. As the article claims, the explosion of publicly available databases housing sequences, structures, and images allows life scientists to make fundamental discoveries without ever getting their hands “wet” at the lab bench. Science Journal calls […]Read More
The Global Cleantech 100 Gala honored and celebrated the achievements of the 2013 Global Cleantech 100 companies, the 100 top innovators in cleantech today.
Two of Claremont Creek Ventures portfolio companies, Alphabet Energy and Clean Power Finance were named to the list to the top 100 Global Cleantech companies.Read More
Congratulations to our portfolio company NuMedii for a publication today in Cancer Discovery, which discusses the use of its technology by Stanford researchers to identify an antidepressant as a potential treatment for small cell lung cancer. NuMedii is a pioneer in the future of pharmacology. As medicine becomes more personalized, every individual will get a […]Read More
Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.